Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHAR Stock Forecast 2025-2026
$9.31
Current Price
$649.74M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHAR Price Targets
+329.6%
To High Target of $40.00
+297.4%
To Median Target of $37.00
+50.4%
To Low Target of $14.00
PHAR Price Momentum
-7.2%
1 Week Change
+15.1%
1 Month Change
+0.1%
1 Year Change
-7.5%
Year-to-Date Change
-15.9%
From 52W High of $11.07
+40.0%
From 52W Low of $6.65
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Pharming (PHAR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PHAR and similar high-potential opportunities.
Latest PHAR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PHAR has a bullish consensus with a median price target of $37.00 (ranging from $14.00 to $40.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $9.31, the median forecast implies a 297.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Carrier at Oppenheimer, projecting a 329.6% upside. Conversely, the most conservative target is provided by Lucy Codrington at Jefferies, suggesting a 50.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHAR Analyst Ratings
3
Buy
0
Hold
0
Sell
PHAR Price Target Range
Low
$14.00
Average
$37.00
High
$40.00
Current: $9.31
Latest PHAR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHAR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 14, 2025 | Oppenheimer | Michael Carrier | Outperform | Maintains | $39.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 9, 2024 | Jefferies | Lucy Codrington | Buy | Initiates | $14.00 |
| Oct 28, 2024 | Oppenheimer | Michael Carrier | Outperform | Maintains | $30.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| May 31, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Aug 3, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 28, 2023 | Oppenheimer | Michael Carrier | Outperform | Maintains | $40.00 |
| Mar 27, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Feb 22, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
Pharming Group N.V. - ADR (PHAR) Competitors
The following stocks are similar to Pharming based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharming Group N.V. - ADR (PHAR) Financial Data
Pharming Group N.V. - ADR has a market capitalization of $649.74M with a P/E ratio of 69.3x. The company generates $320.71M in trailing twelve-month revenue with a -4.4% profit margin.
Revenue growth is +42.3% quarter-over-quarter, while maintaining an operating margin of +1.0% and return on equity of -6.8%.
Valuation Metrics
Market Cap
$649.74M
Enterprise Value
$6.12B
P/E Ratio
69.3x
PEG Ratio
5.5x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
+42.3%
Gross Margin
+89.5%
Operating Margin
+1.0%
Net Margin
-4.4%
EPS Growth
+42.3%
Financial Health
Cash/Price Ratio
+1.7%
Current Ratio
2.8x
Debt/Equity
55.3x
ROE
-6.8%
ROA
+2.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pharming Group N.V. - ADR (PHAR) Business Model
About Pharming Group N.V. - ADR
What They Do
Develops therapeutic proteins for rare diseases.
Business Model
Pharming Group N.V. generates revenue by developing and commercializing therapeutic proteins, particularly through its primary product, RUCONEST®, used to treat hereditary angioedema. The company utilizes proprietary technology and an innovative production platform involving transgenic rabbits to produce high-quality recombinant human proteins, addressing unmet medical needs in the biopharmaceutical sector.
Additional Information
As an American Depositary Receipt (ADR), Pharming Group N.V. provides U.S. investors with access to its biopharmaceutical innovations while facilitating international portfolio diversification. The company's unique approach to protein production and focus on rare diseases positions it as a key player in the healthcare industry, contributing to the development of critical treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
404
CEO
Mr. Fabrice Chouraqui Ph.D., Pharm.D.
Country
Netherlands
IPO Year
2020
Website
www.pharming.comPharming Group N.V. - ADR (PHAR) Latest News & Analysis
Latest News
Pharming Group reports first quarter 2025 financial results and provides business update
10 days ago
Quick Summary
Pharming Group N.V. has released its preliminary unaudited financial report for Q1 2025, covering the period ended March 31.
Why It Matters
Pharming's preliminary financial report could impact stock performance and investor sentiment, indicating potential growth or challenges ahead based on earnings and projections.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharming Group N.V. will hold its Q1 2025 earnings conference call on May 8, 2025, at 7:30 AM ET, featuring CEO Fabrice Chouraqui and CFO Jeroen Wakkerman among others.
Why It Matters
The Q1 2025 earnings call for Pharming Group will provide insights into financial performance and strategic direction, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pharming Group N.V. will hold its 2025 Annual General Meeting on June 11, 2025, at 14:00 CEST. Details and documents are available on the company's investor website.
Why It Matters
The announcement of Pharming's AGM date signals potential shareholder decisions and company direction, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharming Group N.V. will report its preliminary first quarter 2025 financial results on May 8, 2025.
Why It Matters
Pharming's upcoming Q1 2025 financial results may influence stock performance and investor sentiment, providing insights into its revenue, growth, and operational health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
24 days ago
Quick Summary
Pharming Group’s Joenja® (leniolisib) is the first medicine approved for NHS reimbursement for treating APDS in patients aged 12 and older, following NICE's positive guidance.
Why It Matters
Joenja®'s NHS reimbursement approval boosts Pharming's market potential, enhances revenue prospects, and strengthens its position in the growing niche of rare disease treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharming Group N.V. has filed its Annual Report for the year ended December 31, 2024. The report can be accessed on their website under Investors/Financial documents.
Why It Matters
Pharming's Annual Report filing reveals financial performance and strategic direction, impacting stock valuation and investor sentiment. Access to detailed financial data is crucial for informed investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHAR Stock
What is Pharming Group N.V. - ADR's (PHAR) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Pharming Group N.V. - ADR (PHAR) has a median price target of $37.00. The highest price target is $40.00 and the lowest is $14.00.
Is PHAR stock a good investment in 2025?
According to current analyst ratings, PHAR has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHAR stock?
Wall Street analysts predict PHAR stock could reach $37.00 in the next 12 months. This represents a 297.4% increase from the current price of $9.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pharming Group N.V. - ADR's business model?
Pharming Group N.V. generates revenue by developing and commercializing therapeutic proteins, particularly through its primary product, RUCONEST®, used to treat hereditary angioedema. The company utilizes proprietary technology and an innovative production platform involving transgenic rabbits to produce high-quality recombinant human proteins, addressing unmet medical needs in the biopharmaceutical sector.
What is the highest forecasted price for PHAR Pharming Group N.V. - ADR?
The highest price target for PHAR is $40.00 from Michael Carrier at Oppenheimer, which represents a 329.6% increase from the current price of $9.31.
What is the lowest forecasted price for PHAR Pharming Group N.V. - ADR?
The lowest price target for PHAR is $14.00 from Lucy Codrington at Jefferies, which represents a 50.4% increase from the current price of $9.31.
What is the overall PHAR consensus from analysts for Pharming Group N.V. - ADR?
The overall analyst consensus for PHAR is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are PHAR stock price projections?
Stock price projections, including those for Pharming Group N.V. - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 1:07 AM UTC